BETHLEHEM, Pa.—The Renal Therapies Division of B. Braun Medical Inc. has released the new product Adimea, which is a process for real-time monitoring of dialysis effectiveness during treatment.
Adimea, developed by B. Braun and already in use in Europe, is designed for use with B. Braun's Dialog+ Hemodialysis System, provides healthcare professionals with the information they need to give patients the optimal dialysis dose (Kt/V).
The Adimea process, which has been cleared by the U.S. Food and Drug Administration, uses spectroscopy principles to measure dialysis efficiency by determining the reduction in the molar concentration of urinary excreted substances in the spent dialysate by transmitting an ultraviolet (UV) light source through the dialysate.
“The highly reliable and precise instrument allows the online determination and continual monitoring of current Kt/V values throughout the patient's entire treatment,” B. Braun said in a news release.
Adimea requires the entry of only one patient parameter— the patient's weight before dialysis. According to B. Braun, it saves time by eliminating the determination and entry of the urea volume (V), which enables healthcare professionals to focus more attention on patient care.
"Adimea is a very important advancement in renal therapies," said Samuel Amory, vice president, Renal Therapies Division for B. Braun Medical Inc. "It helps healthcare professionals give their patients an optimal dialysis dose and allows them to adjust treatment parameters for the benefit of patients even during treatment."
